DOSE AND TIME-DEPENDENT EFFECTS OF STATINS ON GLYCEMIC STATUS AND THEIR ASSOCIATION WITH NEW ONSET DIABETES MELLITUS
Abstract
of new-onset diabetes mellitus (NODM).
Methods: The study was conducted for a period of 2 months from July 2014 to August 2014. In this cross-sectional observational study, non-diabetic
subjects, who were on statin therapy for more than 2 months were recruited. Participants having previous records of results of diagnostic tests for
blood glucose levels (before starting statin therapy) such as random blood sugar (RBS), fasting blood sugar, and glycated hemoglobin (HbA1c) values
within normal range were included in the study and that values were taken as baseline value. Then another measurement of the same tests repeated
when they enrolled into the study.
Results and Discussion: Of 22 subjects, 3 subjects were on rosuvastatin and the remaining 19 were on atorvastatin. Among the 22 subjects, 17 had
symptoms of hyperglycemia such as polyuria, polydipsia, polyphagia, etc. after starting treatment with statins. It has been found that treatment with
statins increases the risk of new NODM (27%) and there was a significant rise in the mean red blue and green (RBG) levels after therapy. Furthermore,
there was a statistically significant rise in HbA1c values as the doses were increased. The duration of treatment and the body mass index and the type
of statin have not significantly influenced the HbA1c values.
Conclusion: The values of statins in cardiovascular disorders have been clearly established and accepted. Their benefit is undeniable; however, they
need to be taken with caution and care. Physicians should be aware of this adverse drug reaction due to statin therapy and they should monitor the
glycemic control status of the patients during their regular follow-up period.
Keywords: Drug-induced diabetes, Statins, New-onset diabetes mellitus.
Downloads
References
Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J 1995;74(1):14-7.
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
Maji D, Shaikh S, Solanki D, Gaurav K. Safety of statins. Indian J Endocrinol Metab 2013;17:636-46.
Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation 2012;126:e282-4.
Navarese EP, Szczesniak A, Kolodziejczak M, Gorny B, Kubica J, Suryapranata H. Statins and risk of new-onset diabetes mellitus: Is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs 2014;14:79-87.
Garrow JS, Webster J. Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 1985;9:147-53.
American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36 Suppl 1:S11-66.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 2009;32:1924-9.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013;346:f2610.
Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009;57:495-9.
Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al. Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases. BMJ 2014;348:g3244.
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:
-64.
Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-52.
Kryzhanovski V, Eriksson M, Hounslow N, Sponseller CA. Short-term and long-term effects of pitavastatin and simvastatin on fasting plasma glucose in patients with primary hyperlipidemia or mixed dyslipidemia and ≥2 risk factors for coronary heart disease. J Am Coll Cardiol 2012;59:e1659.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.